-+ 0.00%
-+ 0.00%
-+ 0.00%

Merck plans early generic licensing to speed access to once-monthly HIV PrEP pill in 129 LMICs

PUBT·07/24/2026 10:45:41
Listen to the news
Merck plans early generic licensing to speed access to once-monthly HIV PrEP pill in 129 LMICs
  • Merck set early access plans for investigational once-monthly oral HIV PrEP alimatravir (MK-8527) ahead of Phase 3 completion.
  • Strategy targets rapid, broad LMIC rollout post-clearance via royalty-free, non-exclusive generic licensing covering 129 countries.
  • Plans call for regional manufacturing capacity in Africa and Latin America to strengthen supply resilience and support scale-up.
  • Merck will invest early in its own manufacturing to shorten the gap between potential U.S. clearance and LMIC availability.
  • Initial Merck supply is expected to bridge demand until licensed generics secure regulatory clearances and bring production online.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260723155636) on July 24, 2026, and is solely responsible for the information contained therein.